OBJECTIVE: To analyse the early loss of patients to antiretroviral therapy (ART) programmes in resource-limited settings. METHODS: Using data on 5491 adult patients starting ART (median age 35 years, 46% female) in 15 treatment programmes in Africa, Asia and South America with (3) 12 months of follow-up, we investigated risk factors for no follow-up after treatment initiation, and loss to follow-up or death in the first 6 months. FINDINGS: Overall, 211 patients (3.8%) had no follow-up, 880 (16.0%) were lost to follow-up and 141 (2.6%) were known to have died in the first 6 months. The probability of no follow-up was higher in 2003-2004 than in 2000 or earlier (odds ratio, OR: 5.06; 95% confidence interval, CI: 1.28-20.0), as was loss to follow-up (hazard ratio, HR: 7.62; 95% CI: 4.55-12.8) but not recorded death (HR: 1.02; 95% CI: 0.44-2.36). Compared with a baseline CD4-cell count (3) 50 cells/microl, a count < 25 cells/microl was associated with a higher probability of no follow-up (OR: 2.49; 95% CI: 1.43-4.33), loss to follow-up (HR: 1.48; 95% CI: 1.23-1.77) and death (HR: 3.34; 95% CI: 2.10-5.30). Compared to free treatment, fee-for-service programmes were associated with a higher probability of no follow-up (OR: 3.71; 95% CI: 0.97-16.05) and higher mortality (HR: 4.64; 95% CI: 1.11-19.41). CONCLUSION: Early patient losses were increasingly common when programmes were scaled up and were associated with a fee for service and advanced immunodeficiency at baseline. Measures to maximize ART programme retention are required in resource-poor countries.
OBJECTIVE: To analyse the early loss of patients to antiretroviral therapy (ART) programmes in resource-limited settings. METHODS: Using data on 5491 adult patients starting ART (median age 35 years, 46% female) in 15 treatment programmes in Africa, Asia and South America with (3) 12 months of follow-up, we investigated risk factors for no follow-up after treatment initiation, and loss to follow-up or death in the first 6 months. FINDINGS: Overall, 211 patients (3.8%) had no follow-up, 880 (16.0%) were lost to follow-up and 141 (2.6%) were known to have died in the first 6 months. The probability of no follow-up was higher in 2003-2004 than in 2000 or earlier (odds ratio, OR: 5.06; 95% confidence interval, CI: 1.28-20.0), as was loss to follow-up (hazard ratio, HR: 7.62; 95% CI: 4.55-12.8) but not recorded death (HR: 1.02; 95% CI: 0.44-2.36). Compared with a baseline CD4-cell count (3) 50 cells/microl, a count < 25 cells/microl was associated with a higher probability of no follow-up (OR: 2.49; 95% CI: 1.43-4.33), loss to follow-up (HR: 1.48; 95% CI: 1.23-1.77) and death (HR: 3.34; 95% CI: 2.10-5.30). Compared to free treatment, fee-for-service programmes were associated with a higher probability of no follow-up (OR: 3.71; 95% CI: 0.97-16.05) and higher mortality (HR: 4.64; 95% CI: 1.11-19.41). CONCLUSION: Early patient losses were increasingly common when programmes were scaled up and were associated with a fee for service and advanced immunodeficiency at baseline. Measures to maximize ART programme retention are required in resource-poor countries.
Authors: G Chêne; J A C Sterne; M May; D Costagliola; B Ledergerber; A N Phillips; F Dabis; J Lundgren; A D'Arminio Monforte; F de Wolf; R Hogg; P Reiss; A Justice; C Leport; S Staszewski; J Gill; G Fatkenheuer; M E Egger Journal: Lancet Date: 2003-08-30 Impact factor: 79.321
Authors: Joseph Kwong-Leung Yu; Solomon Chih-Cheng Chen; Kuo-Yang Wang; Chao-Sung Chang; Simon D Makombe; Erik J Schouten; Anthony D Harries Journal: Bull World Health Organ Date: 2007-07 Impact factor: 9.408
Authors: A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren Journal: Lancet Date: 1998-11-28 Impact factor: 79.321
Authors: Paul J Weidle; Samuel Malamba; Raymond Mwebaze; Catherine Sozi; Gideon Rukundo; Robert Downing; Debra Hanson; Dorothy Ochola; Peter Mugyenyi; Jonathan Mermin; Badara Samb; Eve Lackritz Journal: Lancet Date: 2002-07-06 Impact factor: 79.321
Authors: Leigh F Johnson; Janne Estill; Olivia Keiser; Morna Cornell; Haroon Moolla; Michael Schomaker; Anna Grimsrud; Mary-Ann Davies; Andrew Boulle Journal: Am J Epidemiol Date: 2014-11-15 Impact factor: 4.897
Authors: Bea Vuylsteke; Gisèle Semdé; Andrew F Auld; Jennifer Sabatier; Joseph Kouakou; Virginie Ettiègne-Traoré; Anne Buvé; Marie Laga Journal: J Acquir Immune Defic Syndr Date: 2015-03-01 Impact factor: 3.731
Authors: Sarah E Gerdts; Bradley H Wagenaar; Mark A Micek; Carey Farquhar; Marina Kariaganis; Juvenal Amos; Sarah Gimbel; James Pfeiffer; Stephen Gloyd; Kenneth Sherr Journal: J Acquir Immune Defic Syndr Date: 2014-06-01 Impact factor: 3.731
Authors: Olivia Keiser; Hannock Tweya; Paula Braitstein; François Dabis; Patrick MacPhail; Andrew Boulle; Denis Nash; Robin Wood; Ruedi Lüthi; Martin W G Brinkhof; Mauro Schechter; Matthias Egger Journal: Trop Med Int Health Date: 2009-12-09 Impact factor: 2.622
Authors: Benjamin H Chi; Albert Mwango; Mark Giganti; Lloyd B Mulenga; Bushimbwa Tambatamba-Chapula; Stewart E Reid; Carolyn Bolton-Moore; Namwinga Chintu; Priscilla L Mulenga; Elizabeth M Stringer; Robert Sheneberger; Peter Mwaba; Jeffrey S A Stringer Journal: J Acquir Immune Defic Syndr Date: 2010-05-01 Impact factor: 3.731
Authors: Mathieu Forster; Christopher Bailey; Martin W G Brinkhof; Claire Graber; Andrew Boulle; Mark Spohr; Eric Balestre; Margaret May; Olivia Keiser; Andreas Jahn; Matthias Egger Journal: Bull World Health Organ Date: 2008-12 Impact factor: 9.408